Last reviewed · How we verify
NCT00768482: PRO-810
A Single Cross-Over, Open-Label Study of the Relative Bioavailability of Probuphine Versus Buprenorphine Sublingual Tablets at Steady State in Patients With Opioid Dependence
Phase 3 trial testing Probuphine (buprenorphine implant) in Opioid Dependence in 9 participants. Terminated before completion.
1 December 2008
Quick facts
| Lead sponsor | Titan Pharmaceuticals |
|---|---|
| Phase | Phase 3 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 1 September 2008 |
| Primary completion | 1 December 2008 |
| Estimated completion | 1 December 2008 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Probuphine (buprenorphine implant) — full drug profile →
- Sublingual Buprenorphine — full drug profile →
Conditions studied
- Opioid Dependence — all drugs for Opioid Dependence →
Sponsor
Titan Pharmaceuticals — full company profile →
Who can join
Adults 18 to 75, any sex, with Opioid Dependence. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Plasma BPN AUC(0-24)during 24 hours at steady state.
Time frame: Day -1, Day -2 and Week 4
Sponsor's own description
This study will measure the amount of buprenorphine found in the blood after taking sublingual buprenorphine tablets versus after implantation with 4 Probuphine (buprenorphine implants).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00768482
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid Dependence
Currently open trials in the same condition.
- NCT05585229 — Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication · Phase 2 · recruiting
- NCT06574009 — Better Options for Chronic Cancer Pain · Phase 4 · recruiting
- NCT06837662 — The MOUD Plus Pilot: Counseling and Peer Support to Support Retention for Medically Complex Patients With Opioid Use Dis · NA · recruiting
- NCT05620940 — A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subj · Phase 1 · recruiting
- NCT05603702 — STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis · Phase 1 · recruiting
Other Titan Pharmaceuticals trials
Trials by the same sponsor.
- NCT03250117 — Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole · Phase 1, PHASE2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00768482 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Titan Pharmaceuticals
- Last refreshed: 27 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00768482.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing